Peak part 1 summary: A phase 3, randomized, open-label, multicenter clinical study of bezuclastinib (CGT9486) and sunitinib combination versus sunitinib in patients with gastrointestinal stromal tumors (GIST).
Timeline
Attention over time
Attention Score history
Login
to access the full charts related to this output.
Activity
Login
to access the full charts related to this output.
Attention Score in Context
Attention Score in Context
This research output has an Altmetric Attention Score of 36. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 17 February 2025.
All research outputs
#1,223,054
of 27,763,300 outputs
Outputs from Journal of Clinical Oncology
#3,257
of 25,937 outputs
Outputs of similar age
#8,775
of 206,088 outputs
Outputs of similar age from Journal of Clinical Oncology
#25
of 130 outputs
Altmetric has tracked 27,763,300 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 95th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 25,937 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 21.2. This one has done well, scoring higher than 87% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 206,088 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 95% of its contemporaries.
We're also able to compare this research output to 130 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 80% of its contemporaries.
